NVCR icon

NovoCure

16.62 USD
+1.41
9.27%
At close Updated May 1, 4:00 PM EDT
Pre-market
After hours
16.45
-0.17
1.02%
1 day
9.27%
5 days
33.92%
1 month
53.32%
3 months
36.34%
6 months
35.9%
Year to date
26.68%
1 year
-7.41%
5 years
-91.8%
10 years
29.74%
 

About: NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Employees: 1,605

0
Funds holding %
of 8,128 funds
0
Analysts bullish %
of 1 analysts
0
Positive news %
of 5 articles
Price charts implemented using Lightweight Charts™